中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2013年
11期
190-191
,共2页
抗肿瘤血管生成%中晚期肝癌%介入治疗
抗腫瘤血管生成%中晚期肝癌%介入治療
항종류혈관생성%중만기간암%개입치료
Anti-angiogenesis therapy%Middle and terminal liver cancer%Interventional chemotherapy
目的探讨抗肿瘤血管生成联合介入治疗中晚期肝癌的临床疗效。方法选取2009年5月~2012年5月我院收治139例中晚期肝癌患者的临床资料进行回顾性分析,按照随机数字表法将其分为观察组72例(抗肿瘤血管生成联合介入化疗)和对照组(仅接受介入化疗)67例,对两组患者的临床疗效和Kamofsky评分进行比较分析。结果(1)观察组的CR+PR率为43.1%明显高于对照组28.4%,两组比较差异有统计学意义(P<0.05);(2)两组患者在Kamofsky 评分比较,观察组的Kamofsky 评分明显高于对照组,差异有统计学意义(P<0.05)。结论抗肿瘤血管生成联合介入治疗中晚期肝癌能有效改善患者生活质量,延长患者生存时间,为治疗肝癌非手术的首选方法。
目的探討抗腫瘤血管生成聯閤介入治療中晚期肝癌的臨床療效。方法選取2009年5月~2012年5月我院收治139例中晚期肝癌患者的臨床資料進行迴顧性分析,按照隨機數字錶法將其分為觀察組72例(抗腫瘤血管生成聯閤介入化療)和對照組(僅接受介入化療)67例,對兩組患者的臨床療效和Kamofsky評分進行比較分析。結果(1)觀察組的CR+PR率為43.1%明顯高于對照組28.4%,兩組比較差異有統計學意義(P<0.05);(2)兩組患者在Kamofsky 評分比較,觀察組的Kamofsky 評分明顯高于對照組,差異有統計學意義(P<0.05)。結論抗腫瘤血管生成聯閤介入治療中晚期肝癌能有效改善患者生活質量,延長患者生存時間,為治療肝癌非手術的首選方法。
목적탐토항종류혈관생성연합개입치료중만기간암적림상료효。방법선취2009년5월~2012년5월아원수치139례중만기간암환자적림상자료진행회고성분석,안조수궤수자표법장기분위관찰조72례(항종류혈관생성연합개입화료)화대조조(부접수개입화료)67례,대량조환자적림상료효화Kamofsky평분진행비교분석。결과(1)관찰조적CR+PR솔위43.1%명현고우대조조28.4%,량조비교차이유통계학의의(P<0.05);(2)량조환자재Kamofsky 평분비교,관찰조적Kamofsky 평분명현고우대조조,차이유통계학의의(P<0.05)。결론항종류혈관생성연합개입치료중만기간암능유효개선환자생활질량,연장환자생존시간,위치료간암비수술적수선방법。
Objective To explore the clinical efficacy of anti-angiogenesis therapy combined with interventional treatment on middle and terminal liver cancer patients.Methods A retrospective analysis of 139 cases patients with middle and terminal liver cancer from May 2009 to May 2012 in our hospital were divided into observation group(72 cases)and control group(67 cases). Observation group was treated with anti-tumor angiogenesis therapy combined with interventional chemotherapy and Control group was treated with only interventional chemotherapy. The clinical curative effect and Kamofsky score were observed and compared in both groups. Results(1)The rate of CR+PR in observation group was obviously higher than that in control group there was significant difference(P < 0.05);(2) After treatment, Kamofsky score in observation group was higher than that in control group, with significant difference (P<0.05). Conclusion The effect of anti-angiogenesis therapy combined with interventional treatment on middle and terminal liver cancer patients is better, is worthy of clinical application.